Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression

Haematologica. 2018 Dec;103(12):e567-e570. doi: 10.3324/haematol.2018.193771. Epub 2018 Jul 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Angiotensin I / administration & dosage
  • Angiotensin I / chemistry
  • Angiotensin I / pharmacology*
  • Animals
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Gemcitabine
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Mice
  • Myelopoiesis / drug effects*
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / chemistry
  • Peptide Fragments / pharmacology*

Substances

  • Immunosuppressive Agents
  • Peptide Fragments
  • Deoxycytidine
  • Angiotensin I
  • angiotensin I (1-7)
  • Gemcitabine